Corticosteroids for Dengue - Why Don't They Work?

Simple item page
dc.date.accessioned2018-09-14T11:15:06Z
dc.date.available2017-07-12T03:36:54Z
dc.date.available2013-10-31en_US
dc.date.available2013-10-31en_US
dc.date.available2013-10-31en_US
dc.date.available2013-10-31en_US
dc.date.available2013-10-31en_US
dc.date.available2013-10-31en_US
dc.date.available2013-10-31en_US
dc.date.available2013-10-31en_US
dc.date.available2018-09-14T11:15:06Z
dc.date.issued2013-12-01en_US
dc.description.abstractBACKGROUND: Dysregulated immune responses may contribute to the clinical complications that occur in some patients with dengue. FINDINGS: In Vietnamese pediatric dengue cases randomized to early prednisolone therapy, 81 gene-transcripts (0.2% of the 47,231 evaluated) were differentially abundant in whole-blood between high-dose (2 mg/kg) prednisolone and placebo-treated patients two days after commencing therapy. Prominent among the 81 transcripts were those associated with T and NK cell cytolytic functions. Additionally, prednisolone therapy was not associated with changes in plasma cytokine levels. CONCLUSION: The inability of prednisolone treatment to markedly attenuate the host immune response is instructive for planning future therapeutic strategies for dengue.
dc.identifier.urihttp://localhost:8080/dspace7/handle/123456789/197
dc.languageEnglishen_US
dc.titleCorticosteroids for Dengue - Why Don't They Work?en_US
dc.typeJournal Article
Files
Collections
Articles